lorazepam has been researched along with Chronic Disease in 27 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hypnotic efficacy and safety of 3 weeks of daily doses of 2 mg lorazepam or 30 mg flurazepam were compared in a double-blind cross-over study in eight chronic insomniacs between the ages of 29 and 60 years." | 9.06 | Comparison of lorazepam and flurazepam as hypnotic agents in chronic insomniacs. ( Chang, H; McClure, DJ; Olah, A; Pecknold, JC; Walsh, J; Wilson, R, 1988) |
| " The speech catatonic symptoms, previously refractory to various antipsychotics, responded promptly to lorazepam, a benzodiazepine with documented efficacy in the treatment of acute catatonia but not chronic catatonia." | 7.72 | Chronic 'speech catatonia' with constant logorrhea, verbigeration and echolalia successfully treated with lorazepam: a case report. ( Lee, JW, 2004) |
| "Acute catatonia of the retarded type responds rapidly to treatment with lorazepam." | 7.69 | Lorazepam treatment of acute and chronic catatonia in two mentally retarded brothers. ( Gaind, GS; Mazurek, MF; Rosebush, PI, 1994) |
| " Therapeutically effective dosage was 3." | 6.71 | [Spectrum of therapeutic efficacy and safety of Lorafen (lorazepam) use for anxiety disorders]. ( Burlakov, AV; Il'ina, NA; Ivanov, SV, 2003) |
| "Patients with primary insomnia typically complain of daytime fatigue and stress and have been shown to have long latencies on the Multiple Sleep Latency Test and increased whole body metabolism." | 6.69 | The use of lorazepam TID for chronic insomnia. ( Arand, DL; Bonnet, MH, 1999) |
| "Catatonia is a syndrome with protean manifestations and multiple aetiologies." | 5.37 | Chronic catatonia with obsessive compulsive disorder symptoms treated with lorazepam, memantine, aripiprazole, fluvoxamine and neurosurgery. ( Jean-Baptiste, M; Mukai, Y; Two, A, 2011) |
| "Hypnotic efficacy and safety of 3 weeks of daily doses of 2 mg lorazepam or 30 mg flurazepam were compared in a double-blind cross-over study in eight chronic insomniacs between the ages of 29 and 60 years." | 5.06 | Comparison of lorazepam and flurazepam as hypnotic agents in chronic insomniacs. ( Chang, H; McClure, DJ; Olah, A; Pecknold, JC; Walsh, J; Wilson, R, 1988) |
| " The case presentation illustrates the role of pregabalin in successful medical management of this chronic pain disorder, as well as the management of common psychiatric morbidities associated with this condition." | 3.74 | Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia. ( Jerome, L, 2007) |
| " The speech catatonic symptoms, previously refractory to various antipsychotics, responded promptly to lorazepam, a benzodiazepine with documented efficacy in the treatment of acute catatonia but not chronic catatonia." | 3.72 | Chronic 'speech catatonia' with constant logorrhea, verbigeration and echolalia successfully treated with lorazepam: a case report. ( Lee, JW, 2004) |
| "Acute catatonia of the retarded type responds rapidly to treatment with lorazepam." | 3.69 | Lorazepam treatment of acute and chronic catatonia in two mentally retarded brothers. ( Gaind, GS; Mazurek, MF; Rosebush, PI, 1994) |
| " The concentration remained almost unaltered after 4 weeks of zuclopenthixol treatment in the schizophrenia group and following various neuroleptic, antidepressant, and anxiolytic medications in the nonschizophrenic patients despite a significant decrease of overt psychopathology assessed by the Brief Psychiatric Rating Scale." | 3.68 | Somatostatin in the cerebrospinal fluid of schizophrenic patients before and after neuroleptic drug treatment. ( Heikkilä, L, 1993) |
| " Therapeutically effective dosage was 3." | 2.71 | [Spectrum of therapeutic efficacy and safety of Lorafen (lorazepam) use for anxiety disorders]. ( Burlakov, AV; Il'ina, NA; Ivanov, SV, 2003) |
| "Patients with primary insomnia typically complain of daytime fatigue and stress and have been shown to have long latencies on the Multiple Sleep Latency Test and increased whole body metabolism." | 2.69 | The use of lorazepam TID for chronic insomnia. ( Arand, DL; Bonnet, MH, 1999) |
| "The prognosis of CCI patients with coma or delirium has not yet been thoroughly studied, but preliminary studies suggest this population is at high risk for detrimental outcomes associated with acute brain dysfunction." | 2.48 | Brain dysfunction in patients with chronic critical illness. ( Girard, TD, 2012) |
| "Catatonia is a syndrome with protean manifestations and multiple aetiologies." | 1.37 | Chronic catatonia with obsessive compulsive disorder symptoms treated with lorazepam, memantine, aripiprazole, fluvoxamine and neurosurgery. ( Jean-Baptiste, M; Mukai, Y; Two, A, 2011) |
| "The incidence of respiratory depression following treatment of prolonged seizures with benzodiazepines is variable in the literature." | 1.31 | Respiratory depression in the acute management of seizures. ( Dooley, JM; Harrison, R; Stewart, WA, 2002) |
| " Firstly, there is a body of research which has shown problems of dependence and habituation in the long-term use of anti-anxiety drugs." | 1.27 | A controlled trial of treatments for generalized anxiety. ( Espie, CA; Gamsu, CV; Hood, EM; Lindsay, WR; McLaughlin, E, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (25.93) | 18.7374 |
| 1990's | 7 (25.93) | 18.2507 |
| 2000's | 8 (29.63) | 29.6817 |
| 2010's | 4 (14.81) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Chatterjee, SS | 1 |
| Mitra, S | 1 |
| Khonglah, D | 1 |
| Singh, OP | 1 |
| Kar, SK | 1 |
| Srivastava, A | 1 |
| Singh, LK | 1 |
| Praharaj, SK | 1 |
| Girard, TD | 1 |
| Mukai, Y | 1 |
| Two, A | 1 |
| Jean-Baptiste, M | 1 |
| Stewart, WA | 1 |
| Harrison, R | 1 |
| Dooley, JM | 1 |
| Ivanov, SV | 1 |
| Il'ina, NA | 1 |
| Burlakov, AV | 1 |
| Mitchell, AR | 1 |
| Spurrell, PA | 1 |
| Gerritse, BE | 1 |
| Sulke, N | 1 |
| Härtter, S | 1 |
| Connemann, B | 1 |
| Schönfeldt-Lecuona, C | 1 |
| Sachse, J | 1 |
| Hiemke, C | 1 |
| Lee, JW | 1 |
| Walker, M | 1 |
| Jerome, L | 1 |
| Emes, CE | 1 |
| Millson, RC | 1 |
| Heikkilä, L | 1 |
| Gaind, GS | 1 |
| Rosebush, PI | 1 |
| Mazurek, MF | 1 |
| Bonnet, MH | 1 |
| Arand, DL | 1 |
| Ungvari, GS | 1 |
| Chiu, HF | 1 |
| Chow, LY | 1 |
| Lau, BS | 1 |
| Tang, WK | 1 |
| Seidl, JJ | 1 |
| Layde, P | 1 |
| Kasich, AM | 1 |
| Dolan, JD | 1 |
| Kamil, R | 1 |
| Yassa, R | 1 |
| Nastase, C | 1 |
| Belzile, L | 1 |
| Adler, L | 1 |
| Angrist, B | 1 |
| Peselow, E | 1 |
| Corwin, J | 1 |
| Rotrosen, J | 1 |
| Chima, P | 1 |
| Beaumont, G | 1 |
| McClure, DJ | 1 |
| Walsh, J | 1 |
| Chang, H | 1 |
| Olah, A | 1 |
| Wilson, R | 1 |
| Pecknold, JC | 1 |
| Lindsay, WR | 1 |
| Gamsu, CV | 1 |
| McLaughlin, E | 1 |
| Hood, EM | 1 |
| Espie, CA | 1 |
| Rickels, K | 1 |
| Case, WG | 1 |
| Downing, RW | 1 |
| Winokur, A | 1 |
2 reviews available for lorazepam and Chronic Disease
| Article | Year |
|---|---|
Brain dysfunction in patients with chronic critical illness.
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Chronic Disease; Coma; Comorbid | 2012 |
Status epilepticus: an evidence based guide.
Topics: Anticonvulsants; Chronic Disease; Critical Care; Drug Administration Routes; Emergency Treatment; Ev | 2005 |
9 trials available for lorazepam and Chronic Disease
| Article | Year |
|---|---|
[Spectrum of therapeutic efficacy and safety of Lorafen (lorazepam) use for anxiety disorders].
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Chronic Disease; Female; Humans; Lo | 2003 |
Improving the acceptability of the atrial defibrillator for the treatment of persistent atrial fibrillation: the atrial defibrillator sedation assessment study (ADSAS).
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Atrial Fibrillation; Chronic Disease; Confidence Interva | 2004 |
The use of lorazepam TID for chronic insomnia.
Topics: Adult; Analysis of Variance; Chronic Disease; Female; Humans; Lorazepam; Male; Middle Aged; Psychomo | 1999 |
Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study.
Topics: Adult; Aged; Anti-Anxiety Agents; Catatonia; Chronic Disease; Cross-Over Studies; Double-Blind Metho | 1999 |
Lorazepam in the management of anxiety associated with chronic gastrointestinal disease: a double-blind study.
Topics: Adult; Aged; Anti-Anxiety Agents; Anxiety; Chronic Disease; Clinical Trials as Topic; Female; Gastro | 1976 |
Efficacy of propranolol in neuroleptic-induced akathesia.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Chronic Disease; Female; Humans; Lorazepam; Ma | 1985 |
Transfer of long term insomniac nitrazepam users to lormetazepam.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Benzodiazepines; Chronic Disease; Double-Blind Method; Femal | 1986 |
Comparison of lorazepam and flurazepam as hypnotic agents in chronic insomniacs.
Topics: Adult; Arousal; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Electroencephalograp | 1988 |
Indications and contraindications for chronic anxiolytic treatment: is there tolerance to the anxiolytic effect?
Topics: Anxiety; Chronic Disease; Clinical Trials as Topic; Clorazepate Dipotassium; Diazepam; Double-Blind | 1985 |
16 other studies available for lorazepam and Chronic Disease
| Article | Year |
|---|---|
Contracture in chronic catatonia and its response to lorazepam.
Topics: Adult; Catatonia; Chronic Disease; Female; Humans; Lorazepam; Schizophrenic Psychology; Treatment Ou | 2020 |
Attributions to new onset catatonic symptoms, late in the course of chronic schizophrenia.
Topics: Amlodipine; Antihypertensive Agents; Antipsychotic Agents; Aripiprazole; Catatonia; Chronic Disease; | 2017 |
Immediate response to lorazepam in a patient with 17 years of chronic catatonia.
Topics: Anticonvulsants; Catatonia; Chronic Disease; Humans; Longitudinal Studies; Lorazepam; Male; Middle A | 2013 |
Chronic catatonia with obsessive compulsive disorder symptoms treated with lorazepam, memantine, aripiprazole, fluvoxamine and neurosurgery.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Catatonia; Chronic Disease; Combined Modality Therapy; Do | 2011 |
Respiratory depression in the acute management of seizures.
Topics: Anticonvulsants; Child; Child, Preschool; Chronic Disease; Diazepam; Drug Therapy, Combination; Huma | 2002 |
Elevated quetiapine serum concentrations in a patient treated concomitantly with doxepin, lorazepam, and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agen | 2004 |
Chronic 'speech catatonia' with constant logorrhea, verbigeration and echolalia successfully treated with lorazepam: a case report.
Topics: Adult; Catatonia; Chronic Disease; Echolalia; Female; Humans; Hypnotics and Sedatives; Lorazepam; Re | 2004 |
Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia.
Topics: Amitriptyline; Analgesics; Anti-Ulcer Agents; Anticoagulants; Antidepressive Agents; Anxiety; Cardio | 2007 |
Risperidone-induced priapism.
Topics: Antipsychotic Agents; Chronic Disease; Drug Therapy, Combination; Humans; Isoxazoles; Lithium Carbon | 1994 |
Somatostatin in the cerebrospinal fluid of schizophrenic patients before and after neuroleptic drug treatment.
Topics: Adult; Borderline Personality Disorder; Chronic Disease; Clopenthixol; Drug Therapy, Combination; Fe | 1993 |
Lorazepam treatment of acute and chronic catatonia in two mentally retarded brothers.
Topics: Adult; Catatonia; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 1994 |
Lorazepam to prevent alcohol withdrawal seizures.
Topics: Adult; Alcoholism; Anti-Anxiety Agents; Chronic Disease; Double-Blind Method; Emergency Service, Hos | 1999 |
[Instead of benzodiazepines. An antidepressant as sleep aid].
Topics: Anti-Anxiety Agents; Antidepressive Agents; Benzodiazepines; Chronic Disease; Clinical Trials as Top | 2001 |
Atypical affective disorder with episodic dyscontrol: a case of von Economo's disease (encephalitis lethargica).
Topics: Adult; Antipsychotic Agents; Carbamazepine; Chlorpromazine; Chronic Disease; Electroencephalography; | 1992 |
Lorazepam as an adjunct in the treatment of auditory hallucinations in a schizophrenic patient.
Topics: Aged; Chronic Disease; Female; Hallucinations; Humans; Lorazepam; Schizophrenia; Schizophrenic Psych | 1989 |
A controlled trial of treatments for generalized anxiety.
Topics: Adult; Anxiety Disorders; Behavior Therapy; Chronic Disease; Cognition; Female; Follow-Up Studies; H | 1987 |